BioCentury
ARTICLE | Company News

Pharmas pitch in on GAVI initiative

January 27, 2015 2:28 AM UTC

The Global Alliance for Vaccine Immunization (GAVI) announced commitments from private sector partners including Pfizer Inc. (NYSE:PFE), GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ), Sanofi (Euronext:SAN; NYSE:SNY), Merck & Co. Inc. (NYSE:MRK) and NewLink Genetics Corp. (NASDAQ:NLNK). GAVI hopes to raise $7.5 billion at a funding conference on Tuesday to deliver vaccines to GAVI-supported countries in 2016-20.

Pfizer reduced the price of its Prevanar 13, a pneumococcal vaccine containing 13 serotypes, from $3.30 per dose to $3.10 per dose in a four-dose course of treatment. The price reduction will be extended to GAVI-supported and GAVI-graduated countries through 2025. ...